In situ intestinal absorption of cyclosporine A solid dispersion in rats

Drug Development and Industrial Pharmacy

Volumn 34, Issue 6, 2008, Pages 627-631

  Liu, Chen ^a   Zhu, Saijie ^a   Zhou, Ying ^a   Wei, Yupu ^a   Pei, Yuanying ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Absorption behavior; Cyclosporine A; In situ circulation; Polyoxyethylene (40) stearate; Solid dispersion

Indexed keywords

CYCLOSPORIN A; DRUG CARRIER; GLYCOPROTEIN P INHIBITOR; MACROGOL STEARATE; QUINIDINE; SODIUM ION;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DIFFUSION; DISPERSION; DRUG ABSORPTION; DRUG SOLUBILITY; INTESTINE ABSORPTION; NONHUMAN; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DIFFUSION; DRUG CARRIERS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 45849125390     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701833948     Document Type: Article

References (23)

1. Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420.
2. Barthe, L., Woodley, J., & Houin, G. (1999). Gastrointestinal absorption of drugs: Methods and studies. Fundam. Clin. Pharmacol., 13, 154-168.
3. Barthe, L., Woodley, J. F., Kenworthy, S., & Houin, G. (1998). An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine. Eur. J. Drug. Metab. Pharmacokinet., 23, 313-323.
4. Berggren, S., Hoogstraate, J., Fagerholm, U., & Lennernäs, H. (2004). Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur. J. Pharm. Sci., 21, 553-560.
5. Boisset, M., Botham, R. P., Haegele, K. D., Lenfant, B., & Pachot, J. I. (2000). Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: Importance of drug ionization in the in vitro prediction of in vivo absorption. Eur. J. Pharm. Sci., 10, 215-224.
6. Chiu, Y. Y., Higaki, K., Neudeck, B. L., Barnett, J. L., Welage, L. S., & Amidon, G. L. (2003). Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm. Res., 20, 749-756.
7. Collett, J. H., Withington, R., & Price, P. H. (1973). An analogue computer study of the dialysis of salicylic acid from micellar solutions of polysorbate 20 and 80. J. Pharm. Pharmacol., 25, 974-981.
8. Deferme, S.,Van Gelder, J., Ingels, F., Van den Mooter, G., De Buck, S., Balzarini, J., Naesens, L., De Clercq, E., Kinget, R., & Augustijns, P. (2002). Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781. Int. J. Pharm., 234, 113-119.
9. Fagerholm, U., Johansson, M., & Lennernäs, H. (1996). Comparison between permeability coefficients in rat and human jejunum. Pharm. Res., 9, 1336-1342.
10. Ford, J. M., & Hait, W. N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-199.
11. Fricker, G., Drewe, J., Huwyler, J., Gutmann, H., & Beglinger, C. L. (1996). Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. Br. J. Pharmacol., 118, 1841-1847.
12. Hebert, M. F. (1997). Contribution of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug. Deliv. Rev., 27, 201-214.
13. Ismailos, G., Reppas, C., Dressman, J. B., & Macheras, P. (1991). Unusual solubility behavior of cyclosporin A in aqueous media. J. Pharm. Pharmacol., 43, 287-289.
14. Lee, Y. J., Chung, S. J., & Shim, C. K. (2001). The prevention of cyclosporine A adsorption to Transwell® surfaces by human plasma. Int. J. Pharm., 224, 201-204.
15. Liu, C., Wu, J. H., Shi, B., Zhang, Y. X., Gao, T. K., & Pei, Y. Y. (2006). Enhancing the bioavailability of Cyclosporine A using solid dispersion containing polyoxyethylene (40) stearate. Drug. Dev. Ind. Pharm., 32, 115-123.
16. Liu, C., Zhu, S. J., Zhou, Y., Wei, Y. P., & Pei, Y. Y. (2006). Enhancement of dissolution of cyclosporine A using solid dispersions with polyoxyethylene (40) stearate. Pharmazie., 8, 681-684.
17. Lo, Y. L. (2003). Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Rel., 90, 37-48.
18. Ren, X. Z., Zhang, J. S., & Wang, H. B. (1997). Studies of absorption mechanism and the best absorption segment of Erythromycin in situ. J. Chin. Pharm. Univ., 28, 17-22.
19. Rodríguez-Ibáñez, M., Nalda-Molina, R., Montalar-Montero, M., Bermejo, M. V., Merino, V., & Garrigues, T. M. (2003). Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: In vitro and in situ inhibition studies. Eur. J. Pharm. Biopharm. Sci., 55, 241-246.
20. Taylor, N. E., Mark, A. E., Vallat, P., Brunne, R. M., Testa, B., & Van Gunteren, W. F. (1993). Solvent dependent conformation and hydrogen bounding capacity of cyclosporin A: Evidence from partition coefficient and molecular dynamic simulations. J. Med. Chem., 36, 3753-3764.
21. Wacher, V. J., Wu, C. Y., & Benet, L. Z. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13, 129-134.
22. Watkins, P. B. (1997). The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug. Deliv. Rev., 27, 161-170.
23. Yu, L. X., Lipka, E., Crison, J. R., & Amidon, G. L. (1996). Transport approaches to the biopharmaceutical design of oral drug delivery system: Prediction of intestinal absorption. Adv. Drug. Del. Rev., 19, 359-376.